~//bj.watch/overview
live

Latest signal

last curated pass Nov 11, 2026 · 8 public entries · source-aware summaries from 6 legacy curated cards plus llm-wiki tweets

# all # health # longevity # nutrition # sleep # concepts

Recent curated signals

Research claim “Lifting weights 3x a week while taking a GLP-1 preserved muscle, had double digit strength gains, and got rid of fat”: the feed’s most exactly verified research relay to date — every claim maps number-for-number onto the T-REx randomized trial published the same morning, with one substitution the post doesn’t make (tirzepatide, not “a GLP-1”) and one beneficiary left unstated (the fat loss is the drug’s, not the lifting’s) Johnson relayed a same-day randomized trial in three sentences: “Lifting weights 3x a week while taking a GLP-1 preserved muscle, had double digit strength gains, and got rid of fat. / Lifting + GLP-1s FTW.” (2,905 likes, 103 reposts, 139 replies; November 11, 20:27 UTC, with a study-figure image). The post names no study, but every line traces to the T-REx trial — “Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial,” Nature Medicine, November 11, 2026 (10.1038/s41591-026-04752-5): 120 adults aged 50–70 with overweight or obesity (no type 2 diabetes) treated with tirzepatide and randomized to thrice-weekly resistance exercise or usual activity for 40 weeks (91% exercise adherence). Each claim verifies number-for-number: “preserved muscle” — total lean soft-tissue loss −3.57 kg with training vs −4.67 kg without (between-group difference 1.09 kg, 95% CI 0.43–1.75, P < 0.001), roughly 24% less lean loss (the university release rounds to 25%); “double digit strength gains” — bench press +10.7%, lat pulldown +15.7%, knee extension +17.5% in the training arm vs declines of 8.4%, 6.5%, and 9.0% without it (all P < 0.001), so the phrase is exact on all three lifts; “got rid of fat” — fat-mass loss was statistically identical between arms (−17.98 vs −17.19 kg, P = 0.700), which verifies the outcome while quietly attributing it to the drug rather than the lifting. Boundaries: the drug is tirzepatide, a GIP/GLP-1 receptor agonist, not semaglutide or “a GLP-1” in general; participants were adults 50–70 with obesity — not Johnson’s regimen or his audience’s baseline; lean soft tissue by DXA is not muscle quality or function; the trial was investigator-initiated with free manufacturer medication but no manufacturer role in design, implementation, or evaluation; and Johnson’s Immortals Rx sells GLP-1 medications, the same commercial adjacency the dashboard records on his September semaglutide mouse-lifespan relay. The dashboard records an attributed research relay with an exactly verified source — not a reader exercise prescription, medication guidance, or medical advice. Research claim “LSD as a longevity therapy?”: a same-morning Aging Cell paper does say LSD pushed rat brain gene activity opposite to human aging — and beat exercise, but only on a transcriptomic reversal ratio; the entire evidence base is rats, mice, and cultured neurons, with zero human results and a Schedule I boundary the post never mentions Johnson posted a psychedelics-and-aging research relay: “LSD as a longevity therapy? / LSD pushes brain gene activity in the opposite direction of aging / In rodents, the effect was stronger than exercise / LSD activated gene networks involved in neuroplasticity and neuronal communication, and reduced amyloid-β damage” (1,250 likes, 116 reposts, 127 replies; November 11, 19:01 UTC, with a study-figure image). The post names no study, but every line traces to one paper published the same morning — Savino, Liaci, Bertani, … Iorio, “Lysergic acid diethylamide reverses aging- and neurodegeneration-associated brain transcriptional programs,” Aging Cell, November 11, 2026 (10.1111/acel.70793; preprint 10.64898/2026.05.26.727809, Human Technopole Milan). Claim-by-claim: “opposite direction of aging” verifies — chronic LSD treatment in the rat medial prefrontal cortex produced gene-expression changes significantly anti-correlated with age-ranked genes across integrated human prefrontal-cortex datasets (3,086 samples spanning ages 2 days to 106 years; Fisher-aggregated p < 2.2 × 10⁻³⁰⁸ for upregulated genes), reproducible across datasets and species. “Stronger than exercise” is true but narrower than it reads: on the paper’s age-reversal p-value ratio, chronic LSD scored highest (average apr = 198) against exercise and enriched-environment positive controls (largest average apr = 136) — a property of transcriptomic signatures, not of brains, bodies, or longevity outcomes. “Activated gene networks involved in neuroplasticity and neuronal communication” verifies — synapse- and dendrite-related GO categories, typically downregulated with aging, were enriched among LSD-upregulated genes. “Reduced amyloid-β damage” verifies in vitro — in primary cortical neurons exposed to 100 nM amyloid-β, subsequent LSD restored MAP2-positive dendritic arborization that amyloid-β had damaged, without affecting architecture on its own. Boundaries: the entire evidence base is preclinical — rats, mice, and cultured neurons; the paper’s own evidence record shows zero human LSD results; the authors name the bulk-tissue limitation themselves (postmortem bulk tissue mixes cell types whose proportions change with age, so single-cell data will be needed); signature reversal is a computational drug-repurposing rationale, not demonstrated slowing of brain aging or cognitive decline; the post names no study; and LSD remains a Schedule I controlled substance in the U.S. outside regulated research and approved access paths. The dashboard records an attributed research relay with a verified same-day source — not evidence that LSD is a longevity therapy, a recommendation, or medical advice. Measurement “My blood glucose is lower than 99.8% of humans”: the feed’s first glucose-percentile claim — the HbA1c/mean-glucose pair is internally consistent under the standard translation (4.6% ↔ eAG 85 vs a claimed 79 mg/dL), and the rust metaphor matches real glycation pathology, but the mortality curve’s own “basement” sits at ~5.5%, 0.9 points above him, and “99.8% of humans” is measured against the world’s diabetic population, not healthy peers Johnson posted the feed’s first glucose-percentile claim: “My blood glucose is lower than 99.8% of humans / best month I’ve had: / > mean 79 mg/dL / > best week 77 mg/dL / > HbA1c 4.6% / Elevated blood glucose rusts from within.” (424 likes, 12 reposts, 80 replies; November 10, 19:16 UTC, with a photo). The internal arithmetic is consistent under the standard translation: the ADAG study (Nathan et al., Diabetes Care 2008; 507 subjects; eAG = 28.7 × A1C − 46.7) puts HbA1c 4.6% at an estimated average glucose of 85.3 mg/dL — within the regression’s ±15.7 mg/dL prediction error of the claimed 79 mg/dL CGM month mean, which back-translates to ~4.4% A1c. But the translation at this end is an extrapolation: Labcorp’s reporting guidance calculates eAG only for HbA1c 5.0–15.0% because “estimations in the nondiabetic range have not been verified,” and a CGM interstitial average is not venous plasma. “Elevated blood glucose rusts from within” works as a glycation metaphor: elevated glucose accelerates nonenzymatic glycation and advanced glycation end-product (AGE) formation, and the AGE–RAGE axis generates reactive oxygen species and inflammatory cascades central to diabetic complications (Nature Reviews Endocrinology 2008, ncpendmet0786) — pathology demonstrated at diabetic-range glucose, not a linear dose–response into the low-normal range. The mortality direction verifies with the stop the post doesn’t mention: EPIC-Norfolk found HbA1c continuously associated with cardiovascular disease and mortality across the nondiabetic distribution, lowest rates below 5% (Khaw et al., BMJ 2001; Ann Intern Med 2004, 10.7326/0003-4819-141-6-200409210-00006), but the cohort’s own 11.2-year reanalysis of 17,196 nondiabetic adults (Diabetologia 2011, 10.1007/s00125-011-2162-0) found the all-cause-mortality hazard “virtually constant in the low range,” rising only above approximately 5.5% — a “basement” below which no mortality benefit of further lowering was demonstrated, and his 4.6% sits 0.9 points below it. Boundaries: “99.8% of humans” is against an unnamed cohort that includes the world’s diabetic and prediabetic population, not healthy peers — the same unpublished-percentile pattern as the Prenuvo and Kernel readouts; the three numbers are summary figures with no device, dataset, or method published; and clinically low HbA1c can also reflect shortened red-cell lifespan (hemolysis, blood loss, anemia) rather than superior metabolic health. The dashboard records an attributed N=1 metabolic readout with verified eAG arithmetic and epidemiologic context — not evidence that pushing HbA1c below 5% extends life, a reader glucose target, or medical advice. Media The feed’s first zero-text post — nine caption-less photos in four seconds, dropped on the one-year anniversary of the live-documented 5 g psilocybin trip and decoded by the thread’s own replies (“You did P. Cubensis”; “its been a year?”) — a memorial that makes no claim and publishes no data Johnson posted an item with no text at all — no caption, no figures, no emoji, rare in the audited record: nine caption-less photos, a root post plus eight self-replies all timestamped within four seconds (20:50:11–20:50:15 UTC, November 9; root: 581 likes, 11 reposts, 33 replies; chain replies 31–71 likes each). The decode comes from the thread itself and the calendar: replies answer the photos with “its been a year? bro what?” and “You did P. Cubensis” — and November 9–10, 2026 is one year after the live-documented psilocybin trip of November 9–10, 2025, when Johnson took 4.67 g dried Psilocybe cubensis (B+ strain, 24.9 mg psilocybin) “under medical supervision, in a legal setting, and with a professional facilitator,” had the experience live-posted by Kate Tolo as trip-sitter, and followed with a trip report (“I felt like a kid finding and exploring a new playground”) and a brain-activity data post, telling curious readers to “speak with your doctor” (Daily Mail, November 11, 2025; LADbible, November 10, 2025; his own November 18, 2025 recap). The original announcement said he would dose once a month for three months to study longevity effects; no published biomarker readout of that series ever appeared, and today’s drop adds none — no text, no claim, no measurement, just the images. Boundaries: the dashboard cannot independently describe the nine photos (no vision verification was performed); the anniversary decode rests on reply context plus timing; psilocybin remains a Schedule I controlled substance in the U.S. outside regulated research and state-regulated access, and his original framing — supervision, legal setting, facilitator, talk to your doctor — is the responsible boundary a zero-text memorial quietly drops; the site’s prior psilocybin coverage is the October Parkinson’s-GDF15 research relay, not personal-use advocacy. The dashboard records an attributed media drop with verified anniversary context — not a recommendation, evidence of benefit, new data, or medical advice. Exercise “To dunk, I need to put 585 lb of force into the floor within 0.2 seconds”: the force number matches published dunk force-plate data for a man his size — but 0.2 seconds is faster than any measured dunk approach, and the lifetime-PR squat behind the “97%” lives only in the video Johnson posted the dunk storyline’s first force budget: “To dunk, I need to put 585 lb of force into the floor within 0.2 seconds. / This squat gets me 97% of the way there on strength. / I’m working on explosiveness. I’m still on the ground too long when jumping. / Side note: this is the most I’ve ever squatted.” (2,196 likes, 28 reposts, 286 replies; November 9, 17:26 UTC, with a 12.7-second video). The force figure reads as a plausible peak ground-reaction force: the only published dunk force-plate study (Slovak Journal of Sport Science; 10 recreational dunkers, 89 kg, 73.7 cm verticals) recorded peak takeoff forces of 3,158–3,207 N on two-leg approaches — roughly 715 lb, about 3.6× body weight — so 585 lb (2,602 N) is the same published multiple for a ~163 lb jumper. But the 0.2-second window runs ahead of the entire measured record: the same study’s concentric phases lasted 0.311–0.820 seconds depending on approach, none as fast as 0.2 s; and the “97% of the way there on strength” split mirrors the literature’s actual finding that dunking is strength plus power — peak power, not force alone, marked the strongest outputs (6,262 W on the stationary two-leg approach) — while rate of force development is precisely the “explosiveness” he says he lacks, making the self-diagnosis directionally sound. Boundaries: the arithmetic implies a squat in the high-500s lb (97% of 585), but the post’s text names no number — the lift itself lives in the attached video with no independent or meet record, so the lifetime-PR claim is unverifiable; his evidence is one 12.7-second clip, not a measured force plate; “still on the ground too long” is a self-coaching observation; the 3.6× anchor comes from ten recreational dunkers, not from him; and the jump from the tracked October 25 deadlift (385 lb ×5, estimated ~445 lb 1RM) to an implied high-500s squat is a storyline jump the post does not document. The dashboard records an attributed N=1 training disclosure with verified force-plate context — not a reader training program, evidence of a measured 585 lb/0.2 s takeoff, or medical advice. Sleep “it’s 8:35 pm / i’m asleep”: the feed’s first line-by-line sleep-stage narration — and its one checkable number verifies almost perfectly against textbook architecture (8:35 pm onset → 10:03 pm REM is an 88-minute latency, inside every published 60–100-minute band) Johnson posted the feed’s first stage-by-stage sleep narration: “it’s 8:35 pm / i’m asleep / fell asleep in five min / my resting heart rate is 41 bpm / now dropping into deep sleep / brain clearing out waste / rem sleep at 10:03 pm / emotional processing / then, you know what happens next…” (1,370 likes, 13 reposts, 105 replies; November 9, 04:35 UTC). The physiology narrated is real and the one checkable figure verifies: 8:35 pm onset → 10:03 pm first REM is an 88-minute REM latency, squarely inside the textbook band — sleep-medicine references put the first REM episode at roughly 60–100 minutes after onset (about 90 on average) with ~90–120-minute cycles thereafter; deep sleep concentrating early in the night is exactly normal architecture (N3 predominates in the first third); “brain clearing out waste” paraphrases the glymphatic hypothesis, in which natural sleep expands the brain’s interstitial space (13–15% awake → 22–24% asleep) and speeds clearance of metabolites including amyloid-β (Xie et al., Science 2013, 10.1126/science.1241224 — rodent evidence, with the mechanism still actively debated); and “emotional processing” matches the leading REM hypothesis (“sleep to forget, sleep to remember”), in which REM selectively strengthens emotional memories and modulates their charge — a hypothesis with substantial support, not settled fact. The 41 bpm resting heart rate continues the tracked RHR storyline (the October “Sovereignty Index” and the CMAJ 2016 mortality gradient), an N=1 wearable figure, not a reader target. Boundaries: the post contains no data — no device named, no hypnogram shown — it narrates a standard night’s architecture as if it were a live report of his own measured sleep, ending on a wink (“then, you know what happens next…”); a five-minute sleep-onset latency sits at the fast end of the typical 10–20 minutes and carries no diagnostic weight in self-report; the narrated schedule is species-general textbook physiology, not evidence his sleep followed it that night. The dashboard records an attributed sleep-narration post whose one checkable figure verifies against sleep-medicine references — not a reader sleep schedule, evidence that this exact architecture occurred, or medical advice. Commercial “Scan of your heart to make sure all is well”: the feed’s first disclosed Prenuvo paid partnership turns five cardiac-MRI percentiles into a Blueprint-marketplace product plug — the heart-disease framing verifies against the American Heart Association, but the scan’s own materials say it cannot diagnose heart disease or see artery blockages, and the “20 yr old” percentiles are another unpublished private report Johnson posted the feed’s first explicitly disclosed Prenuvo partnership: “Scan of your heart to make sure all is well. / Heart disease is the #1 cause of death, also the most preventable chronic disease. / I partnered with Prenuvo to make this easy for you. / Below are my results to encourage you to find out yours.” (339 likes, 8 reposts, 40 replies; November 9, 00:45 UTC, with an attached results photo), following up one minute later that “This scan is in the Blueprint marketplace” (23 likes, 1 repost, 4 replies; 00:46 UTC — a self-reply in the same thread, pointing to the same Blueprint-marketplace link attached to his October 29 sauna-marketplace reply). The framing statistics verify in direction: heart disease is the leading cause of death in the U.S. and globally, and the American Heart Association says as much as 80% of heart disease and stroke is preventable — via risk-factor management (Life’s Essential 8: blood pressure, lipids, glucose, weight, tobacco, activity, diet, sleep), restated in the AHA’s March 31, 2026 dietary-guidance statement (10.1161/CIR.0000000000001435). The product is real: Prenuvo’s Advanced Heart Health Scan, launched with Myocardial Solutions on August 27, 2026, uses FDA-cleared MyoStrain® analysis to quantify myocardial strain across 48 ventricular segments (37 left, 11 right), summarized as a MyoHealth® score — the share of segments with normal contraction — plus estimated ejection fraction; his radiologist quote names the same instrument (“Bryan’s Myohealth assessment indicates age equivalent myocardial function to a healthy person in their early 20s”). Boundaries: Prenuvo’s own product page states the report “does not diagnose heart disease, assess for coronary artery disease, or replace standard cardiac testing” and that MyoStrain cannot see blockages, plaque, or coronary artery disease — so “make sure all is well” overstates what the scan can establish; the five percentiles (“top 5% of 20 yr olds” myocardial function, more blood pumped than “95% of 20 yr old men,” higher ejection fraction and stronger contraction than “80% of healthy 20 yr olds,” “better synched than 92% of healthy 20 yr olds”) summarize an unpublished private report against an undisclosed normative cohort — the same pattern as the October 27 whole-body-MRI readout, where no professional society recommends screening MRI of asymptomatic people; the AHA’s preventability case rests on risk-factor management, not imaging, and “most preventable chronic disease” is gloss beyond the AHA’s wording; “One minor concern was identified and was most likely a measurement artefact” is an undisclosed finding with an unpublished interpretation; the post is advertising for a partner product sold through his own marketplace, an incentive structure the post does not mention; engagement figures drift and were read at curation time (November 9, ~03:35 UTC). The dashboard records an attributed commercial partnership with verified product and epidemiologic context — not evidence that heart scanning improves outcomes, a validated age-equivalence metric, or medical advice. Opinion “Deep focus replacing choppy social media has increased my life fulfillment by 10x”: an unfalsifiable self-report whose observable half verifies — the audit window’s two longest posting gaps sit exactly where the claimed break sits — wrapped around an announcement tease Johnson posted an attention-and-fulfillment self-report: “I’ve been in deep focus for the past few days cooking up some really fun stuff that I’m excited to share. My time on social media has been minimal. The deep focus replacing choppy social media has increased my life fulfillment by 10x. I really hope that we transition soon to a world where we can still play human social games without it needing screens or fragmenting the mind.” (315 likes, 6 reposts, 32 replies; November 9, 01:39 UTC — the newest item on the timeline at curation time, November 9, ~03:35 UTC). The claim’s core number is an unfalsifiable self-report — “life fulfillment” has no metric, baseline, or measurement, and “10x” is rhetorical magnitude, not data. But the observable half verifies in the audit record: the 40-post window shows its two longest posting gaps exactly where the claimed break sits — 1 day 20 hours 14 minutes from the November 5, 21:13 UTC market meme to the November 7, 17:28 UTC aphorism, then a second 31-hour gap from that aphorism to the November 9, 00:45 UTC heart-scan partnership post — a cadence drop consistent with “minimal” social-media time, though the partnership advertisement itself arrived inside the claimed quiet window, so the break is reduced cadence, not absence. “Cooking up some really fun stuff” is an announcement tease with no content disclosed — the same pattern as prior preview posts that later resolved into product launches. The screens-and-fragmentation framing extends the feed’s long-running attention ideology (the October “motivation problem is a sleep problem” post, the year’s screen-time remarks) without new evidence. The dashboard records an attributed behavior self-report with a verified cadence change — not evidence that quitting social media increases fulfillment, a wellness directive, or medical advice.

// Reference paths

Move from feed to dossiers

Each route keeps source trails and medical caution visible.
Protocol Health

Habits, Longterm, and Don’ts for measurement loops, sleep consistency, oral care, exercise, and experimental-intervention caution.

 Protocol Longevity

Habits, Longterm, and Don’ts for biomarkers, healthspan basics, critiques, and low-confidence immortality claims.

 Protocol Nutrition

Habits, Longterm, and Don’ts for plant-led meals, Blueprint products, microplastics claims, and metabolic-drug caveats.

 Protocol Sleep

Habits, Longterm, and Don’ts for bedtime discipline, front-loading examples, and metric caution from tweet-backed sources.

 Reference Concepts

39 source-aware glossary entries, including concepts without dedicated wiki pages yet.

 entity Blueprint

Blueprint is bryan-johnson's longevity protocol, product company, and public measurement system. It began as Project Blueprint, an N=1 effort to measure Johnson's organs and biological aging, and later became a consumer

 concept Blueprint Protocol

The Blueprint Protocol is bryan-johnson's closed-loop health system: measure body state, consult scientific evidence, implement interventions, measure again, and update. Johnson treats the body as a system whose organs a

 concept Don't Die

Don't Die is bryan-johnson's community slogan, longevity philosophy, and civilizational frame. The official Don't Die page describes a community “united in defeating all causes of human and planetary death and building a

 concept Biomarker-driven longevity protocols

A biomarker-driven longevity protocol is a health system that treats the body as a measurable control system: collect biomarkers, choose interventions, re-measure, and iterate. project-blueprint is the most visible curre

 Signal Metrics

Inspect source velocity by range, content type, and fallback API state.